Angiosarcoma

Oncology·MeSH: Hemangiosarcoma

Prevalence

0.1 / 100K

12 drugs in development·2 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
RP1 (vusolimogene oderparepvec)	Replimune Group, Inc. (REPL)

Phase 2(5)

Drug	Company
Inactivated Sinopharm or Sinovac COVID-19 vaccine	ENANTA PHARMACEUTICALS INC (ENTA)
Pegfilgrastim	ENANTA PHARMACEUTICALS INC (ENTA)
Pfizer-BioNTech vaccine COVID-19 vaccine	ENANTA PHARMACEUTICALS INC (ENTA)
SARS-CoV-2 mRNA Vaccine ARCT-021	ENANTA PHARMACEUTICALS INC (ENTA)
SVN53-67/M57-KLH Peptide Vaccine	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(6)

Drug	Company
Dendritic Cell Tumor Fusion Vaccine	ENANTA PHARMACEUTICALS INC (ENTA)
Filgrastim	ENANTA PHARMACEUTICALS INC (ENTA)
mRNA plus Lysate-loaded Dendritic Cell Vaccine	ENANTA PHARMACEUTICALS INC (ENTA)
NK Cell Infusion	ENANTA PHARMACEUTICALS INC (ENTA)
PEGYLATED-INTERFERON ALPHA-2A	ENANTA PHARMACEUTICALS INC (ENTA)
Peripheral Blood Stem Cell Infusion	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 12 drugs in development for Angiosarcoma across 2 companies.

There are 7 clinical trials targeting Angiosarcoma tracked by BioSniper.

The estimated prevalence of Angiosarcoma is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.